313 related articles for article (PubMed ID: 25199216)
1. Role of HDL in those with diabetes.
Santos-Gallego CG; Rosenson RS
Curr Cardiol Rep; 2014 Sep; 16(9):512. PubMed ID: 25199216
[TBL] [Abstract][Full Text] [Related]
2. Role of HDL in those with diabetes.
Santos-Gallego CG; Rosenson RS
Curr Cardiol Rep; 2014 Aug; 16(8):512. PubMed ID: 24950673
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
5. HDL-Targeting Therapeutics: Past, Present and Future.
Zakiev E; Feng M; Sukhorukov V; Kontush A
Curr Pharm Des; 2017; 23(8):1207-1215. PubMed ID: 27799042
[TBL] [Abstract][Full Text] [Related]
6. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Chapman MJ; Le Goff W; Guerin M; Kontush A
Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
[TBL] [Abstract][Full Text] [Related]
8. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
[TBL] [Abstract][Full Text] [Related]
9. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
[TBL] [Abstract][Full Text] [Related]
10. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.
Mahdy Ali K; Wonnerth A; Huber K; Wojta J
Br J Pharmacol; 2012 Nov; 167(6):1177-94. PubMed ID: 22725625
[TBL] [Abstract][Full Text] [Related]
12. Fibrates and niacin: is there a place for them in clinical practice?
Wierzbicki AS; Viljoen A
Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
[TBL] [Abstract][Full Text] [Related]
13. Low high-density lipoprotein cholesterol: current status and future strategies for management.
Singh V; Sharma R; Kumar A; Deedwania P
Vasc Health Risk Manag; 2010 Oct; 6():979-96. PubMed ID: 21127701
[TBL] [Abstract][Full Text] [Related]
14. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
15. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
Otocka-Kmiecik A; Mikhailidis DP; Nicholls SJ; Davidson M; Rysz J; Banach M
Prog Lipid Res; 2012 Oct; 51(4):314-24. PubMed ID: 22609245
[TBL] [Abstract][Full Text] [Related]
16. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
17. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
18. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
19. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
20. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
Sharma RK; Singh VN; Reddy HK
Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]